Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

Bronchomycn

Financiado

Cerrado

First in class epithelial Barrier enhancing medicine for respiratory diseases

Chronic obstructive pulmonary disease (COPD) is a respiratory disorder that presents airway epithelial barrier failure (EBF) for which there are no efficient drugs, being a leading cause of chronic morbidity. According to the Wor... ver más

31/05/2017

EpiEndo

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

EpiEndo Pharmaceuticals ehf No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2017-05-31

SMEInst-05-2016-2017: Supporting innovative SMEs in the h...

I+D

Cerrada hace 8 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

EpiEndo

50.00K€ | Lider

Proyectos interesantes

BRONCHOTHELIN

Medical Technol...

Pharmaceuticals

4M€ Cerrado

PID2021-125947OB-I00

Medical Technol...

Data Science

333K€ Cerrado

DESARROLLO DE UNA NUEVA ESPECIALIDAD GENÉRICA...

Medical Technol...

Pharmaceutical...

437K€ Cerrado

RESPIRE

Medical Technol...

Pharmaceuticals

4M€ Cerrado

RTC-2016-4698-1

Medical Technol...

Pharmaceutical...

562K€ Cerrado

EFICACIA CLÍNICA DE UN TRATAMIENTO EN LA REDU...

Medical Technol...

Clinical Resear...

2M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 4 meses Fecha Inicio: 2017-01-26
Fecha Fin: 2017-05-31

Líder del proyecto

EpiEndo Pharmaceuticals ehf No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Chronic obstructive pulmonary disease (COPD) is a respiratory disorder that presents airway epithelial barrier failure (EBF) for which there are no efficient drugs, being a leading cause of chronic morbidity. According to the World Health Organization 64 million people suffered COPD in 2004. The EU-28 and USA accounted for 23 and 12.7 million people respectively, which caused near 200,000 deaths. As a consequence of the medical complications of COPD the economic burden has been estimated as € 48.4 and € 29.3 billion in EU-28 and USA respectively EpiEndo, aims at commercializing a new drug which will be able to save € 27 billion to EU-28 and USA. Bronchomycn belong to Barriolides, a new class of compounds that provide effective treatment against EBF. Bronchomycn is structurally based on the well-known azithromycin, but lacks antibiotic activity and it acts by decreasing the permeability of the pulmonary epithelium membrane to toxins and infectious agents. We have been working since 2014 in collaboration with the Stem Cell Research Unit and the University Hospital and now our product is in the early in-vivo stages, for what we have invested € 0.5 Mill. In order to get Bronchomycn to the market, we will start the Clinical studies in 2018 and we expect that current knowledge about side effects of azithromycin speed up the process so that the product will be ready for commercialization in 2021. During Phase 1 we will prepare the preclinical studies in rodents and clinical studies and defining end-points and regulatory requirements, prepare IPR protection plan, etc. The market for Bronchomycn is the respiratory therapeutics market which was valued at € 24.8 billion in 2015. We plan to start our sales in Europe in 2022 and USA in 2024, so that by 2026 our turnover will reach €807 Mill. Therefore, we have decided to continue with Bronchomycn for what we need an additional investment of € 49 Mill, that considering a 5-years forecast will give us a ROI of 14.2

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores